Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > BioAlliance Pharma Receives Market Approval for Loramyc® in the United Kingdom and Denmark

Abstract:
BioAlliance Pharma SA (Paris: BIO) today announces, following the end of the European Mutual Recognition Procedure last December (with France as Reference Member State) that it has just received the Marketing Authorisation for Loramyc® in the UK and Denmark.

BioAlliance Pharma Receives Market Approval for Loramyc® in the United Kingdom and Denmark

PARIS, France | Posted on January 9th, 2008

The grant of the Marketing Authorisation in the UK represents an important milestone for BioAlliance Pharma especially with the payment of €2.5 million by its partner SpePharm, according to the terms of the agreement signed in March 2007, which led to the creation of the SpeBio JV for the distribution of Loramyc® in Europe.

"We are delighted of this European success which confirms the quality and the efficiency of our development and regulatory teams and experts. Currently being launched in France, Loramyc® will be present on the European market in 2008 as planned. The other main European countries should grant their Marketing Authorisation for Loramyc® in the very near future", stated Dominique Costantini Chief Executive Officer.

####

About BioAlliance Pharma SA
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc®) in France and the compound is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad® in oral herpes (based on the same Lauriad® muco-adhesive technology as Loramyc®, which enables targeted release at the disease site) and doxorubicin Transdrug® in primary liver cancer (based on the Transdrug® nanoparticle technology, designed specifically for intracellular targeting of resistant cells). The company is also developing a new therapeutic entities program focused on the oncology and HIV markets.

In 2007, the company has established strategic alliances for commercializing Loramyc® in Europe (with JV SpeBio) and the USA (with Par Pharmaceutical).

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007 under the number R. 07-031, which is available on the AMF website ( http://www.amf-france.org ) or on BioAlliance Pharma S.A.'s website ( http://www.bioalliancepharma.com ).

For press releases and other company information, visit www.bioalliancepharma.com.

For more information, please click here

Contacts:
BioAlliance Pharma SA
Dominique Costantini
+33 1 45 58 76 01
President and CEO

or
ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

OSU researchers prove magnetism can control heat, sound: Team leverages OSC services to help confirm, interpret experimental findings May 29th, 2015

Two UCSB Professors Receive Early Career Research Awards: The Department of Energy’s award for young scientists acknowledges UC Santa Barbara’s standing as a top tier research institution May 29th, 2015

Global Carbon Nanotubes (CNT) Market Expected To Reach USD 3.42 Billion By 2022 May 29th, 2015

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

Govt.-Legislation/Regulation/Funding/Policy

OSU researchers prove magnetism can control heat, sound: Team leverages OSC services to help confirm, interpret experimental findings May 29th, 2015

Physicists precisely measure interaction between atoms and carbon surfaces May 28th, 2015

Linking superconductivity and structure May 28th, 2015

Chemists discover key reaction mechanism behind the highly touted sodium-oxygen battery May 28th, 2015

Nanomedicine

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27th, 2015

Seeing the action: UCSB researchers develop a novel device to image the minute forces and actions involved in cell membrane hemifusion May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Announcements

OSU researchers prove magnetism can control heat, sound: Team leverages OSC services to help confirm, interpret experimental findings May 29th, 2015

Two UCSB Professors Receive Early Career Research Awards: The Department of Energy’s award for young scientists acknowledges UC Santa Barbara’s standing as a top tier research institution May 29th, 2015

Global Carbon Nanotubes (CNT) Market Expected To Reach USD 3.42 Billion By 2022 May 29th, 2015

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project